IPO - Translational Development Acquisition Corp.

Form Type: 8-K

Filing Date: 2024-12-31

Corporate Action: Ipo

Type: New

Accession Number: 000110465924132921

Filing Summary: On December 24, 2024, Translational Development Acquisition Corp. consummated its initial public offering (IPO) of 17,250,000 units, including 2,250,000 units issued due to the full exercise of the underwriter’s over-allotment option. Each unit consists of one Class A ordinary share with a par value of $0.0001 and one-half of one redeemable warrant, with each whole warrant allowing the purchase of one Class A ordinary share at an exercise price of $11.50. The units were sold at $10.00 each, totaling gross proceeds of $172,500,000. Concurrently, the company completed a private placement of 7,075,000 warrants, generating an additional $7,075,000. The net proceeds of $174,225,000 from both the IPO and private placement were placed in a U.S.-based trust account. The audited balance sheet reflecting these proceeds is included as Exhibit 99.1 to the current report.

Form Type: 8-K

Filing Date: 2024-12-27

Corporate Action: Ipo

Type: New

Accession Number: 000110465924132134

Filing Summary: Translational Development Acquisition Corp. announced the consummation of its initial public offering (IPO) on December 24, 2024. The offering included 17,250,000 units, with an additional 2,250,000 units sold to cover over-allotments, resulting in total gross proceeds of $172,500,000. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable for $11.50. The company entered into various agreements related to the IPO, including Underwriting, Warrant, Investment Management Trust, Registration Rights, Private Placement Warrants Purchase, and Administrative Services Agreements on December 23, 2024. A total of 7,075,000 warrants were privately placed with the Sponsor and Underwriter. Additionally, on December 20, 2024, the company appointed new directors and updated its articles of association in connection with the IPO. The proceeds from the IPO are placed in a U.S.-based trust account. The company issued press releases regarding the pricing and closing of the IPO on December 23 and 24, 2024, respectively.

Form Type: 424B4

Filing Date: 2024-12-23

Corporate Action: Ipo

Type: New

Accession Number: 000110465924131277

Filing Summary: Translational Development Acquisition Corp. is a blank check company seeking to raise $150 million through an initial public offering (IPO) of 15,000,000 units at a price of $10.00 per unit. Each unit consists of one Class A ordinary share and one-half of a redeemable warrant, with each whole warrant allowing the purchase of one Class A ordinary share at $11.50. The company has not yet identified a specific target for its initial business combination and has no substantive discussions with potential targets. Following the offering, the company has 18 months to complete an initial business combination; if not completed, it will redeem public shares at a price equal to the trust account balance divided by outstanding public shares. The offering includes provisions for sponsor warrants and private placements totaling up to 7,075,000 warrants. The company has secured a 45-day over-allotment option for the underwriters. The units are to be listed on the Nasdaq under the symbol 'TDACU', with separate trading of Class A ordinary shares and warrants expected after 52 days. Investors face risks associated with potential dilution from the founder and warrant shares. The issuer also highlights various risks related to the investment in its securities and reserves the right to amend its internal governing documents concerning shareholder approvals and timelines. Investors will bear the risks of potential conflicts of interest among sponsors and management regarding the selection of business combination targets.

Form Type: CORRESP

Filing Date: 2024-12-19

Corporate Action: Ipo

Type: New

Accession Number: 000110465924130181

Filing Summary: Translational Development Acquisition Corp. is requesting the acceleration of the effective date for its Registration Statement on Form S-1 (File No. 333-282763) to December 23, 2024, at 4:00 p.m. Eastern time. This request is made by BTIG, LLC, representing the underwriters of the offering, pursuant to Rule 461 under the Securities Act of 1933. Additionally, BTIG has confirmed it distributed sufficient copies of the Preliminary Prospectus dated December 18, 2024, to prospective underwriters and dealers, ensuring compliance with Rule 15c2-8 under the Securities Exchange Act of 1934.